-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MOvUoK2n2tPy0Dn/LVJBKwxlchRomjvvXaadhUzn5Xdpar9lBxyeR3yQYUP8/Kw7 yQCsmOWaddBdeNF0shJ7xQ== 0001104659-06-049093.txt : 20061207 0001104659-06-049093.hdr.sgml : 20061207 20060726190415 ACCESSION NUMBER: 0001104659-06-049093 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PONIARD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 BUSINESS PHONE: 2062817001 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 FORMER COMPANY: FORMER CONFORMED NAME: NEORX CORP DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

Perkins Coie LLP

Faith M. Wilson

PHONE:

206.359.3237

FAX:

206.359.4237

EMAIL:

fwilson@perkinscoie.com

 

July 27, 2006

VIA EDGAR

Securities and Exchange Commission
100 F Street, N.E.
Washington, DC  20549

Re:        Poniard Pharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
File No. 0-16614

Ladies and Gentlemen:

On behalf of Poniard Pharmaceuticals, Inc., we are transmitting the Preliminary Proxy Statement on Schedule 14A, including annexes, which are being filed electronically via the EDGAR system.  We expect that the mailing of the definitive proxy statement will occur in mid-August 2006, after the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2006 has been filed with Commission.  The Form 10-Q, as well the Company’s Form 10-K for the year ended December 31, 2005, will be incorporated by reference into, and delivered to the Company’s shareholders with, the definitive proxy statement.  The Company will furnish the Commission a draft of the financial statements to be included in the Form 10-Q as soon as practicable after the financial statements have been prepared.

In the event there are any questions concerning the enclosed materials, please feel free to contact me at (206) 359-3237.

Sincerely,

 

Perkins Coie LLP

 

/s/ Faith M. Wilson

 

Faith M. Wilson

 

 

Enclosure

 

 

 

cc:    Poniard Pharmaceuticals, Inc.

 

 


 -----END PRIVACY-ENHANCED MESSAGE-----